Evaluation and management of pulmonary hypertension in systemic sclerosis

Current Opinion in Rheumatology

Volumn 15, Issue 6, 2003, Pages 761-765

  Preston, Ioana R ^a   Hill, Nicholas S ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

Diagnosis; Markers; Pathophysiology; Pulmonary hypertension; Systemic sclerosis

Indexed keywords

BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; MARKER; PROSTACYCLIN; SILDENAFIL; SITAXSENTAN; UNIPROST;

ANEMIA; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE EXACERBATION; EDEMA; ELECTROCARDIOGRAM; EVALUATION; HUMAN; LIVER DYSFUNCTION; LUNG ARTERY PRESSURE; LUNG FUNCTION TEST; OXIMETRY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW; SYSTEMIC SCLEROSIS; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT OUTCOME;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; COMORBIDITY; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION, PULMONARY; INCIDENCE; MALE; MIDDLE AGED; RISK FACTORS; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 0742269647     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200311000-00013     Document Type: Review

References (32)

1. Stupi AM, Steen VD, Owens GR, et al.: Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986, 29:515-524.
2. Ungerer RG, Tashkin DP, Furst D, et al.: Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am J Med 1983, 75:65-74, 3
3. Salerni R, Rodnan GP, Leon DF, et al.: Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (systemic sclerosis). Ann Intern Med 1977, 86:394-399.
4. Steen V: Systemic sclerosis and related syndromes: clinical features. In Primer on Rheumatic Diseases. Edited by Klippel JHCL, Stone JH, Weyand CM. Atlanta: Atlanta Arthritis Foundation; 1997:267-272.
5. Campbell E, Harris B: Idiopathic pulmonary fibrosis clinical conference. Arch Intern Med 1981, 141:771-774.
6. Scorza R, Caronni M, Bazzi S, et al.: Post-menopause is the main risk factor for developing isolated pulmonary hypertension in systemic sclerosis. Ann N Y Acad Sci 2002, 966:238-246.
7. Steen V, Medsger TA Jr: Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003, 48:516-522.
8. Feuerstein N, Spiegel S, Mond J: The nuclear matrix protein, numatrin (B23), is associated with growth factor-induced mitogenesis in Swiss 3T3 fibroblasts and with T lymphocyte proliferation stimulated by lectins and anti-T cell antigen receptor antibody. J Cell Biol 1988, 107:1629-1642.
9. Imai H, Ochs R, Kiyosawa K, et al.: Nucleolar antigens and autoantibodies in hepatocellular carcinoma and other malignancies. Am J Pathol 1992, 140: 859-870.
10. Ulanet DB, Wigley FM, Gelber AC, et al.: Autoantibodies against B23, a nucleolar phosphoprotein, occur in systemic sclerosis and are associated with pulmonary hypertension. Arthritis Rheum 2003, 49:85-92. This study describes a novel antibody that is increased in systemic sclerosis patients with lung involvement.
11. Jinnin M, Ihn H, Yamane K, et al.: Plasma plasmin-alpha2-plasmin inhibitor complex levels are increased in systemic sclerosis patients with pulmonary hypertension. Rheumatology (Oxford) 2003, 42:240-243.
12. Saito E, Fujimoto M, Hasegawa M, et al.: CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 2002, 109:1453-1462.
13. Morse J, Barst R, Horn E, et al.: Pulmonary hypertension in systemic sclerosis spectrum of disease: lack of bone morphogenetic protein receptor 2 mutations. J Rheumatol 2002, 29:2379-2381. This study outlines the genetic differences between PPH and PAH related to systemic sclerosis.
14. Currie P, Seward J, Chan K, et al.: Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler- catheterization study in 127 patients. J Am Coll Cardiol 1985, 6:750-756.
15. Arcasoy S, Christie J, Ferrari V, et al.: Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003, 167:735-740. This important study demonstrates that echocardiography can often over-and underestimate PA pressures in patients with advanced lung disease.
16. Barst RJ, Rubin LJ, Long WA, et al.: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996, 334:296-302.
17. Badesch DB, Tapson VF, McGoon MD, et al.: Continuous intravenous epoprostenol for pulmonary hypertension due to the systemic sclerosis spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000, 132:425-434.
18. Simonneau G, Barst R, Galie N, et al.: Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertensions double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002, 165:800-804.
19. Vancheeswaran R, Magoulas T, Efrat G, et al.: Circulating endothelin-1 levels in systemic sclerosis subsets-a marker of fibrosis or vascular dysfunction? J Rheumatol 1996, 21:1838-1844.
20. Giaid A, Yanagisawa M, Langleben D, et al.: Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993, 328: 1732-1739.
21. Soma S, Takahashi H, Muramatsu M, et al.: Localization and distribution of endothelin receptor subtypes in pulmonary vasculature of normal and hypoxia-exposed rats. Am J Respir Cell Mol Biol 1999, 20:620-630.
22. Rubin LJ, Badesch DB, Barst RJ, et al.: Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002, 346:896-903. This study establishes the efficacy of nonselective endothelin receptor antagonist bosentan on functional capacity in patients with different forms of PAH.
23. Sitbon O, Badesch D, Channick R, et al.: Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1 -year follow-up study. Chest 2003, 124:247-254. This open-label trial shows the long-term effects of bosentan in patients with PAH.
24. Barst R, Rich S, Widlitz A, et al.: Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest 2002, 212:1860-1868. This study shows that sitaxsentan improved functional capacity in PAH patients.
25. Barst R, Langleben D, Frost A, et al.: Sitaxsentan, a selective ETA antagonist, improves hemodynamics in pulmonary arterial hypertension (PAH). Am J Respir Crit Care Med 2003, 167:A273 (abstract).
26. Barst R, Langleben D, Frost A, et al.: Sitaxsentan, a selective ETA antagonist, improves exercise capacity and NYHA functional class in pulmonary arterial hypertension (PAH). Am J Respir Crit Care Med 2003, 167:A440 (abstract).
27. Giordano D, De Stefano M, Citro G, et al.: Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain. Biochim Biophys Acta 2001, 28:16-27.
28. Molina J, Lucero E, Luluaga S, et al.: Systemic lupus erythematosus-associated pulmonary hypertension: good outcome following sildenafil therapy. Lupus 2003, 12:321-323.
29. Wilkens H, Guth A, Konig J, et al.: Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001, 104:1218-1222.
30. Ghofrani H, Wiedemann R, Rose F, et al.: Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002, 136:515-522.
31. Kawut SM, Taichman DB, Archer-Chicko CL, et al.: Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003, 123:344-350.
32. Kuhn KP, Byrne DW, Arbogast PG, et al.: Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med 2003, 167:580-586. In this cohort study of PAH patients on epoprostenol, systemic sclerosis patients had a worse outcome compared with PPH patients.